A bilingual (Mandarin-English) investor presentation made at BIOSeedin Innovation Partnering Smmit Autumn 2026 describing AdAlta's:

• Goal of using cell therapies as living drugs to bring new hope to patients with solid cancers

• “East to West” business model that sources the most promising Asian cell therapies and makes them accessible to Western patients and pharma companies in a de-risked, capital efficient manner

• Collaboration with Shanghai Cell Therapy Group on EW 001, a CAR-T cell therapy that has demonstrated hard to achieve complete responses lasting up to two years and longer in advanced mesothelioma, a deadly cancer asspciated with asbestos expsoure

• Progress and plans to establish manufacturing and development collaborations in China to achieve even greater speed and cost efficiency in globalising regional cellular immunotherapies.